1 completed, 1 unknown, 1 withdrawn. 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Completed 1, Unknown 1, Withdrawn 1 |
Follow Blade Therapeutics: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| RESPIRARE - Efficacy and Safety of Cudetaxestat in Patients With Idiopathic Pulmonary Fibrosis (IPF) Cudetaxestat (BLD-0409), Control: Matching Placebo - Idiopathic Pulmonary Fibrosis | Phase 2 | Unknown | Blade Therapeutics | 200 | 2022-05-31 | 2022-05-18 |
| Safety and Antiviral Activity of BLD-2660 in COVID-19 Hospitalized Subjects BLD-2660 - Sars-CoV-2, Covid19 | Phase 2 | Completed | Blade Therapeutics | 120 | 2020-05-04 | 2022-04-06 |
| Safety, Pharmacodynamics, and Pharmacokinetics of Orally Administered BLD-2660 in Subjects With IPF BLD-2660, Control: Placebo - Idiopathic Pulmonary Fibrosis | Phase 2 | Withdrawn | Blade Therapeutics | 2019-12-15 | 2021-03-04 |
Idiopathic Pulmonary Fibrosis (2) · COVID-19 (1) · Pulmonary Fibrosis (1)
Brazil (1) · United Kingdom (1) · United States (1)